Your email has been successfully added to our mailing list.

×
0 0 -0.0583657587548638 -0.0622568093385213 -0.066147859922179 -0.046692607003891 -0.163268482490272 -0.143579766536965
Stock impact report

Epizyme up 25% premarket on removal of partial clinical hold on tazemetostat [Seeking Alpha]

Epizyme, Inc. (EPZM) 
Last epizyme, inc. earnings: 2/24 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: epizyme.com
Company Research Source: Seeking Alpha
Epizyme (NASDAQ: EPZM ) is up   premarket on modest volume in reaction to its announcement that the FDA has lifted the partial clinical hold on U.S. enrollment of new patients in its tazemetostat clinical trials. Enrollment is being reopened, including its Phase 2 study in EZH2-activating mutation-positive non-Hodgkin lymphoma. See all stocks on the move » Now read: Biotech Analysis Central Pharma News: Teva's U.S. Erosion, Denali's Preliminary Results, Epizyme's Trial Shutdown » Subscribe for full text news in your inbox Show less Read more
Impact Snapshot
Event Time:
EPZM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for EPZM alerts
Opt-in for
EPZM alerts

from News Quantified
Opt-in for
EPZM alerts

from News Quantified